Infectious complications following nonmyeloablative allogeneic hematopoietic stem cell transplantation

Transplant Infectious Disease

Volumn 5, Issue 3, 2003, Pages 132-139

  Busca, Alessandro ^a   Locatelli, F ^a   Barbui, A ^a   Ghisetti, V ^a   Cirillo, D ^a   Serra, R ^a   Audisio, E ^a   Falda, M ^a  

^a Bone Marrow Transplant Unit   (Italy)

Author keywords

Bacteremia; Fungal infections; Hematopoietic stem cell transplantation; Infectious complications; Viral infections

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CIDOFOVIR; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; FLUCONAZOLE; FOSCARNET SODIUM; GANCICLOVIR; IDARUBICIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; PENTAMIDINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RITUXIMAB; STEROID; THIOTEPA; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ANTIGEN DETECTION; ARTICLE; BACTEREMIA; BONE MARROW CELL; CAUSE OF DEATH; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; EVALUATION; FEBRILE NEUTROPENIA; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GRANULOCYTOPENIA; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; INCIDENCE; INFECTION COMPLICATION; INFECTION RISK; LUNG ASPERGILLOSIS; MYCOSIS; NEUTROPENIA; NONMYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; RELAPSE; SOLID TUMOR; STATISTICAL SIGNIFICANCE; SURVIVAL; VIREMIA;

ADULT; AGED; BACTERIAL INFECTIONS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MYCOSES; MYELOABLATIVE AGONISTS; TRANSPLANTATION CONDITIONING;

EID: 0242291869     PISSN: 13982273     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3062.2003.00027.x     Document Type: Article

References (46)

1. GRATWOHL A, HERMANS J, PEARCE R, et al. Hematopoietic precursor cell transplant, main risk factors. Blood 1995:86:618a.
2. MOLINA AJ, STORB RF. Hematopoietic stem cell transplantation in older adults. In: ROWE JM, LAZARUS HM, CARELLA AM, eds. Handbook of Bone Marrow Transplantation (1st edn). London, UK: Martin Dunitz, 2000:111-137.
3. SULLIVAN KM, STORB R, BUCKER CD, et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 1989:320:828-834.
4. BERTZ H, BURGER JA, KUNZMANN R, FINKE J. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect. Leukemia 1997:11:281-283.
5. VAN BESIEN KM, DE LIMA M, GIRALT SA, et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant 1997:19:977-982.
6. GIRALT S, ESTEY E, ALBITAR M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997:89:4531-4536.
7. SLAVIN S, NAGLER A, NAPARSTEK E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic disease. Blood 1998:91:756-763.
8. MCSWEENEY PA, NIEDERWIESER D, SHIZURU JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effect. Blood 2001:97:3390-3400.
9. NIEDERWIESER D, MARIS M, SHIZURU JA, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003:4:1620-1629.
10. BUSCA A, BOSI A, VAN LINT MT, et al. Transplant-related mortality (TRM) in patients receiving reduced versus conventional intensity thiotepa-cyclophosphamide (THIO-CY) conditioning: the impact of stem cell source in 176 consecutive patients allografted from HLA-identical siblings. Bone Marrow Transplant 2001:27 (Suppl. 1):S282.
11. CHAKRAVERTY R, PEGGS K, CHOPRA R, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002:99:1071-1078.
12. JUNGHANSS C, MARR KA, CARTER RA, et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 2002:8:512-520.
13. MARTINO R, CABALLERO MD, CANALS C, et al. Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2001:28:341-347.
14. RUIZ-ARGUELLES GJ, GÒMEZ-ALMAGUER D, LÓPEZ-MARÍNEZ B, PONCE-DE-LEÒN S, CANTÙ-RODRIGUEZ OG, JAIME-PÉREZ JC. No cytomegalovirus-related deaths after nonablative stem cell allografts. Hematology 2002:7:95-99.
15. MOHTY M, FAUCHER C, VEY N, et al. High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation. Bone Marrow Transplant 2000:26:251-255.
16. MOSSAD SB, AVERY RK, LONGWORTH DL, et al. Infectious complications within the first year after nonmyeloablative allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2001:28:491-495.
17. HAGEN EA, STERN H, PORTER D, et al. High rate of invasive fungal infections following nonmyeloablative allogeneic transplantation. Clin Infect Dis 2003:36:9-15.
18. CHAKRABARTI S, MACKINNON S, CHOPRA R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002:99:4357-4363.
19. NAKAI K, KANDA Y, MINEISHI S, et al. Suspected delayed immune recovery against cytomegalovirus after reduced-intensity stem cell transplantation using anti-thymocyte globulin. Bone Marrow Transplant 2002:29:237-241.
20. JUNGHANSS C, BOECKH M, CARTER RA, et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002:99:1978-1985.
21. ASCIOGLU S, REX JH, DE PAUW B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002:34:7-14.
22. GLUCKSBERG H, STORB R, FEFER A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974:18:295-304.
23. SHULMAN HM, SULLIVAN KM, WEIDEN PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinico-pathologic study of 20 Seattle patients. Am J Med 1980:69:204-211.
24. BACIGALUPO A, LAMPARELLI T, BRUZZI P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001:98:2942-2947.
25. KHOURY H, KASHYAP A, ADKINS DR, et al. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow Transplant 2001:27:1059-1064.
26. MARR KA, CARTER RA, BOECKH M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002:13:4358-4366.
27. MEYERS JD. Fungal infections in bone marrow transplant patients. Semin Oncol 1990:17:10-13.
28. WILLIAMSON ECM, MILLAR MR, STEWARD CG, et al. Infections in adults undergoing unrelated bone marrow transplantation. Br J Haematol 1999:104:560-568.
29. CAILLOT D, CASANOVAS PO, BERNARD A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997:15:139-147.
30. SULAHIAN A, BOUTBOUL F, RIBAUD P, et al. Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and one pediatric hematology units during a 4-year prospective study. Cancer 2001:91:311-318.
31. MAERTENS J, VERHAEGEN J, LAGROU K, et al. Screening for circulating galactomannan as a non-invasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001:97:1604-1610.
32. MARR KAS, SEIDEL K, SLAVIN MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000:96:2005-2061.
33. HERBRECHT R, DENNING DW, PATTERSON TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002:347:408-415.
34. MAERTENS J, RAAD I, SABLE CA, et al. Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin (CAS) in adults with invasive aspergillosis (IA) refractory or intolerant to amphotericin B (AMB). AMB lipid formulations (lipid AMB), or azoles. Proceedings of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto 2000, Poster 1103, p. 370.
35. DENNING DW. Therapeutic outcome of invasive aspergillosis. Clin Infect Dis 1996:23:608-615.
36. EINSELE H, HEBART H, KAUFFMANN-SCHNEIDER C, et al. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant 2000:25:757-763.
37. NGUYEN Q, CHAMPLIN R, GIRALT S, et al. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow recipients. Clin Infect Dis 1999:28:618-623.
38. BACIGALUPO A, MORDINI N, PITTO A, et al. Transplantation of HLA-mismatched CD34+ selected cells in patients with advanced malignancies: severe immunodeficiency and related complications. Br J Haematol 1997:98:760-766.
39. GOR D, SABIN C, PRENTICE HG, et al. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transplant 1998:21:597-605.
40. PÉRÉZ-SIMÒN JA, KOTTARIDIS PD, MARTINO R, et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 2002:100:3121-3127.
41. BAINTON RD, BYRNE JL, DAVY BJ, et al. CMV infection following nonmyeloablative allogeneic stem cell transplantation using Campath. Blood 2002:100:3843-3844.
42. NAKAMURA R, CORTEZ K, SOLOMON S, et al. High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 2002:30:235-242.
43. GRABER C, DE ALMEIDE KNF, CHILDS R, et al. CMV reactivation in nonmyeloablative HSCT. Bone Marrow Transplant 2001:27:775.
44. BORNHAUSER M, THIEDE C, SCHULER U, et al. Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin. Bone Marrow Transplant 2000:26:119-125.
45. MULLIGHAN CG, HEATLEY S, DOHERTY K, et al. Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation. Blood 2002:99:3524-3529.
46. ROCHA V, FRANCO RF, PORCHER R, et al. Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002:100:3908-3918.